GE Healthcare’s PET project
This article was originally published in The Gray Sheet
Executive Summary
Hammersmith Hospital in London is enrolling subjects for GE's first-in-man clinical study evaluating the use of a positron emission tomography (PET) agent to detect the location and growth patterns of tumors. According to a June 5 release, the imaging agent has a biological mechanism to track angiogenesis, or the formation of new blood vessels in the body, necessary for the growth of many tumors. The study will quantify response to therapy by imaging Stage IV metastatic tumors of the breast before and after cycles of chemotherapy. A recent report on FDA's Critical Path initiative highlighted the role for imaging in developing cancer products (1"The Gray Sheet" March 27, 2006, p. 5). GE says it is "looking forward to collaborating with the pharmaceutical industry to enable more targeted therapies"...